OSTX OS Therapies Inc.: Accounting Value per Share

Public company logo of OS Therapies Inc. (OSTX)

OS Therapies Incorporated (OSTX) is developing a closed-loop research cycle by integrating hospitals through its proprietary targeted therapy platforms. The book value per common share reflects the asset balance, with the value of -0.26 serving as the current metric. A monopoly in the treatment of pediatric bone tumors provides the company with significant pricing power. Patent protection and stringent FDA regulations create an insurmountable barrier to entry for new players.

OS Therapies Inc. (OSTX) - Accounting Value per Share from 08/02/2024 to 10/28/2026
Manufactured product of ostherapies.com

Book value per share determines the portion of net assets attributable to a single security, serving as an indicator of the fundamental capital safety margin. The price action of the book value per share reflects the operational resilience of OS Therapies Incorporated (OSTX), demonstrating the company's ability to accumulate resources to implement costly immunotherapy developments based on the listeria platform against solid tumors.

Competitor analysis for OS Therapies Incorporated

Accounting Value per Share BeiGene Corp ONC|Halozyme Corp (HALO) - Book Price of a Share|Accounting Value per Share Revolution Medicines|ascentage.com (AAPG) - Equity per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share RADX|Artiva Biotherapeutics, Inc. - Net Assets per Single Share|Net Asset Value per Share ANL (adlainortye.com)|Net Assets per Single Share VERU|TPST - Net Assets per Share|Accounting Value per Share Xilio (XLO)|Renovaro Inc. (RENB) - Accounting Value of a Share|MURA - Accounting Value per Share|Kairos Pharma (KAPA) - Book Price of a Share|OKUR - Book Value per Share|Accounting Value of a Share CytoMed|Curis, Inc. - Book Value per Share|Net Asset Value per Share APLM (apollomicsinc.com)|Net Assets per Single Share Tharimmune, Inc.|Accounting Value of a Share Advanced Biomed Inc. ADVB|Genprex - Book Value per Share|CLDI: Book Value per Share|Net Assets per Single Share Sunshine Biopharma, Inc. (SBFM)|Xenetic Biosciences, Inc. (XBIO) - Share Book Value|SLRX: Book Value per Share|Net Assets per Share purple-biotech.com|American Oncology Network - Book Value per Share|Net Asset Value per Share BGNE (BeiGene Ltd.)|Net Assets per Single Share CKPT|ELEV - Net Assets per Share|Accounting Value per Share iCAD Corp (ICAD)|IKNA - Accounting Value of a Share|Notable Labs - Book Value per Share|VIRX (Viracta Therapeutics, Inc.) - Net Assets per Share|Net Assets per Single Share MorphoSys Corp (MOR)|Equity per Share NAYA Biosciences Corp|Book Value per Share AAPGV (Ascentage Pharma Group)